New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
10:37 EDTBMYBristol-Myers nearing important test of support, levels to watch
On a multi-year chart, the $48 level stands out as one to watch. That level was a pivot high nearly a year ago to date before a corrective phase began which then lead to a stronger rally. Following that rally the $48 area has been tested numerous times as support. What may be different this time is that any test of $48 is coming after the long-term uptrend has been called into doubt by the price action of the last several months. A breakdown below $48 could mark a major top with subsequent bearish price action. In that event next support below would be at $46.54. Equally a strong bounce off $48 might signal a bullish turn for the shares, but a move to well above $50 would be required to fill the most recent bearish gap on the chart.
News For BMY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent BMY news | >>
October 30, 2014
15:02 EDTBMYLeerink medical devices analyst holds an analyst/industry conference call
Subscribe for More Information
13:02 EDTBMYBristol-Myers, Lonza expand manufacturing agreement
Subscribe for More Information
12:59 EDTBMYOn The Fly: Midday Wrap
Subscribe for More Information
10:49 EDTBMYBristol-Myers rallies after CheckMate -063 Opdivo study results
Subscribe for More Information
09:04 EDTBMYBristol-Myers announces CheckMate -063 Opdivo study results
Bristol-Myers Squibb announced results from CheckMate -063, a Phase 2 single-arm, open-label study of Opdivo With approximately 11 months of minimum follow up, the objective response rate was 15% as assessed by an independent review committee using RECIST 1.1 criteria and the median duration of response was not reached. The estimated one-year survival rate was 41% and median overall survival was 8.2 months.These data will be presented during the Plenary Session at the 2014 Chicago Multidisciplinary Symposium on Thoracic Oncology on October 31. Bristol-Myers Squibb has proposed the name Opdivo, which, if approved by health authorities, will serve as the trademark for nivolumab.
07:15 EDTBMYASCO / ASTRO / IASLC to hold symposium
Subscribe for More Information
05:49 EDTBMYStocks with implied volatility movement; ARCP BMY
Subscribe for More Information
October 28, 2014
07:04 EDTBMYBristol-Myers enters agreement to acquire F-star Alpha, rights to FS102
Subscribe for More Information
07:03 EDTBMYBristol-Myers enters agreement to acquire F-star Alpha, rights to FS102
October 27, 2014
20:54 EDTBMYLeerink's major pharma analyst holds an analyst/industry conference call
Subscribe for More Information
October 24, 2014
16:02 EDTBMYOptions Update; October 24, 2014
Subscribe for More Information
11:15 EDTBMYBristol-Myers says has capacity for large deal
Subscribe for More Information
10:42 EDTBMYBristol-Myers sees coming in closer to high end of FY14 EPS guidance
Subscribe for More Information
10:10 EDTBMYBristol-Myers to host conference call
Conference call to review data presented at the Chicago Multidisciplinary Symposium on Thoracic Oncology (CMSTO) will be held on October 31 at 2:30 pm. Webcast Link
07:35 EDTBMYBristol-Myers reports Q3 Eliquis revenue $216M
Reports Q3 Baraclude revenue $325M, Sprycel revenue $385M, Yervoy revenue $350M. Reports Q3 Abilify revenue $449M, Orencia revenue $444M.
07:33 EDTBMYBristol-Myers confirms FY14 adjusted EPS view $1.70-$1.80, consensus $1.78
Cuts FY14 GAAP EPS view to $1.15-$1.25 from $1.50-$1.60. Both GAAP and non-GAAP guidance assume current exchange rates and that the R&D tax credit will be extended by Congress in 2014. Sees FY14 worldwide revenue $15.2B-$15.8B, consensus $15.58B. Also sees: Full-year gross margin as a percentage of revenues between 75% and 76%. Advertising and promotion expense decreasing in the mid-teen-digit range. Marketing, sales and administrative expenses decreasing in the mid-single-digit range. Research and development expenses growing in the mid-single-digit range. An effective tax rate of 19% - 20%.
07:31 EDTBMYBristol-Myers reports Q3 adjusted EPS 45c, consensus 42c
Subscribe for More Information
October 23, 2014
15:39 EDTBMYNotable companies reporting before tomorrow's open
Subscribe for More Information
October 21, 2014
07:15 EDTBMYFDA to hold workshop on breast cancer drug development
Subscribe for More Information
October 20, 2014
07:19 EDTBMYIBC Life Sciences to hold a conference
Subscribe for More Information
1 | 2 | all recent BMY news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use